This trial is active, not recruiting.

Condition knee osteoarthritis
Treatments regenexx sd, exercise therapy
Sponsor Regenerative Sciences, LLC
Start date January 2014
End date December 2016
Trial size 50 participants
Trial identifier NCT02034032, MM-03-K


The primary objective of this study is to evaluate the efficacy of Regenexx SD compared to Exercise Therapy at three months. Historical comparison will be made to Total Knee Arthroplasty for treatment of knee osteoarthritis at 1 and 2 years.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model crossover assignment
Masking open label
Primary purpose treatment
(Active Comparator)
Regenexx-SD (Same Day) is a bone marrow based injection procedure.
regenexx sd
stem cell treatment
(Active Comparator)
Subjects in the Exercise Therapy group will attend an initial session with a trained Physical Therapist. During that session the physical therapist will instruct the subject in a home exercise program and instructions about activity limitations. The subject's progress will also be followed by the Physical Therapist during the 6 week follow-up visit with further instructions provided.
exercise therapy
exercise therapy control

Primary Outcomes

Knee Society Scores
time frame: 3 months

Secondary Outcomes

KSS means difference between Regenexx SD and historical TKA data
time frame: 1 year
KSS means difference between Regenexx SD and historical TKA data
time frame: 2 year

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

Inclusion Criteria: 1. Voluntary signature of the IRB approved Informed Consent 2. Ages 18 to 70 3. Diagnosis of Knee osteoarthritis 4. Kellgren-Lawrence Grade 2 or 3 on X-Ray 5. BMI of <30 6. Minimum flexion to 110 degrees 7. Varus under 12 degrees/Valgus under 15 degrees 8. Instability in any plane less than 2 mm translation 9. ACL intact and no history of ACL reconstruction 10. Knee Society 100 point score > 65 11. If bilateral arthritis, subject must be able and willing to delay treatment of the second side for at least 6 months 12. Candidate is able to follow Regenexx medication guidelines 13. Patient agrees to return for periodic assessment protocol 14. Patient must execute all required documents 15. Patient must be appraised of Clinical Trial Exclusion Criteria: 1. History of infection of the joint in the last five years 2. Intra-articular PRP, steroid or viscosupplementation in the last three months 3. Previous knee surgery within the last 6 months 4. Flexion contracture over 15 degrees 5. Low back pain with radiculopathy or with "significant" radiographic changes 6. History of immunosuppressive or chemotherapy in the last five years 7. Systemic neurological disease 8. HIV positive or chronic hepatitis 9. Any significant co-morbidity that in the opinion of the investigator should exclude the subject from the study

Additional Information

Official title A Randomized Controlled Trial of Regenexx™ SD Versus Exercise Therapy for Treatment of Knee Osteoarthritis With Historical Comparison to Total Knee Arthroplasty
Principal investigator Mitchell Sheinkop, M.D.
Description The study is single center, prospective, randomized, controlled trial to include 50 subjects, 25 treated with Regenexx SD and 25 treated with Exercise Therapy for treatment of knee osteoarthritis. Subjects will be enrolled within 60 days prior to Regenexx-SD injection or initiation of Exercise Therapy and take part in follow-up visits for two years following treatment. A preoperative visit will occur at the time of enrollment; follow-up visits will occur at the clinical site at 6 weeks, 3 months, 6 months, 12 months, and 24 months post injection. Subjects in the control, exercise therapy arm, will have the opportunity to cross-over to the study treatment arm at or after the 3 month visit and then continue to be followed through 24 months. Subjects will complete the study following the 2 year follow-up visit. They will be withdrawn from the study prematurely if a revision occurs. The study subjects will be compared to a historical total knee arthroplasty group. Data of the TKA group subjects will be reviewed retrospectively after it is retrieved from the clinical database. The TKA group will consist of patients who underwent TKA for knee osteoarthritis. The inclusion criteria of age and BMI will be applied to these subjects.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by Regenerative Sciences, LLC.